Table 3. Univariate and multivariate Cox analysis of 5-year OS in patients with FOS in training cohort (n=83).
| Characteristics | Total, n | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |||
| Age | 83 | 1.02 (1.00–1.04) | 0.03 | 1.02 (0.99–1.04) | 0.13 | |
| Race | ||||||
| Others | 9 | Reference | ||||
| White | 61 | 0.80 (0.27–2.35) | 0.68 | |||
| Black | 13 | 1.63 (0.48–5.51) | 0.44 | |||
| Sex | ||||||
| Male | 41 | Reference | ||||
| Female | 42 | 0.74 (0.37–1.47) | 0.40 | |||
| SEER stage | ||||||
| Distant | 7 | Reference | Reference | |||
| Localized | 37 | 0.13 (0.05–0.35) | <0.01 | 0.10 (0.03–0.31) | <0.01 | |
| Regional | 39 | 0.17 (0.06–0.45) | <0.01 | 0.21 (0.08–0.58) | <0.01 | |
| Surgery | ||||||
| Yes | 77 | Reference | Reference | |||
| No | 6 | 2.52 (0.96–6.62) | 0.06 | 1.87 (0.52–6.79) | 0.33 | |
| Radiation | ||||||
| Yes | 8 | Reference | Reference | |||
| No | 75 | 0.35 (0.14–0.84) | 0.02 | 0.33 (0.09–1.15) | 0.08 | |
| Chemotherapy | ||||||
| No | 25 | Reference | ||||
| Yes | 58 | 1.02 (0.49–2.13) | 0.96 | |||
OS, overall survival; FOS, fibroblastic osteosarcoma; CI, confidence interval; SEER, Surveillance, Epidemiology, and End Results.